Dermatologic adverse events to chemotherapeutic agents, Part 1: Cytotoxic agents, epidermal growth factor inhibitors, multikinase inhibitors, and proteasome inhibitors

Seminars in Cutaneous Medicine and Surgery

Volumn 33, Issue 1, 2014, Pages 28-39

  Kyllo, Rachel L ^a   Anadkat, Milan J ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; AMIFOSTINE; ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; ANTIINFECTIVE AGENT; BETHANECHOL; CELECOXIB; CORTICOSTEROID; CYTOTOXIC AGENT; DOXEPIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; HYALURONIDASE; ISEGANAN; LIDOCAINE; MINOXIDIL; MISOPROSTOL; PENTOXIFYLLINE; PILOCARPINE; PRAMOCAINE; PREGABALIN; PROPANTHELINE BROMIDE; PROTEASOME INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; PYRIDOXINE; RAZOXANE; SODIUM THIOSULFATE; SUCRALFATE; TETRACHLORODECAOXIDE; TETRACYCLINE DERIVATIVE; UNINDEXED DRUG; CYTOTOXIN; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN KINASE INHIBITOR;

ACUTE FEBRILE NEUTROPHILIC DERMATOSIS; ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS; ALLERGIC REACTION; ALOPECIA; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BLEEDING; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER THERAPY; CHEWING GUM; COOLING; CRYOTHERAPY; DARIER DISEASE; DEPIGMENTATION; DESQUAMATION; DYSESTHESIA; EDEMA; ERYTHEMA; EXTRAVASATION; FACE ERYTHEMA; FIBROSIS; HALO NEVUS; HAND FOOT SKIN REACTION; HAND FOOT SYNDROME; HIDRADENITIS; HUMAN; HYPERPIGMENTATION; HYPERTRICHOSIS; HYPOPIGMENTATION; INFLAMMATORY INFILTRATE; LEUKOCYTOCLASTIC VASCULITIS; LOCAL THERAPY; LOW LEVEL LASER THERAPY; MACULOPAPULAR RASH; META ANALYSIS (TOPIC); MUCOSA INFLAMMATION; NAIL DYSTROPHY; ORAL MUCOSITIS; PAPULAR RASH; PAPULE; PAPULOPUSTULAR RASH; PARONYCHIA; PHASE 2 CLINICAL TRIAL (TOPIC); POSTINFLAMMATORY HYPERPIGMENTATION; PRURITUS; PYODERMA GANGRENOSUM; RASH; RAYNAUD PHENOMENON; SCAR FORMATION; SKIN DISCOLORATION; SKIN DISEASE; SKIN MANIFESTATION; SKIN TUMOR; SYSTEMATIC REVIEW (TOPIC); SYSTEMIC THERAPY; SYSTEMIC VASCULITIS; ULTRAVIOLET RADIATION; VASCULITIS; XEROSIS; CHEMICALLY INDUCED DISORDER; CONTRAST MEDIUM EXTRAVASATION; DRUG ANTAGONISM; DRUG HYPERSENSITIVITY; METABOLISM; NAIL DISEASE; NEOPLASM; NEUTROPHIL; PIGMENT DISORDER; RADIATION DERMATITIS; REVIEW;

ALOPECIA; CYTOTOXINS; DRUG HYPERSENSITIVITY; EDEMA; ERYTHEMA; EXTRAVASATION OF DIAGNOSTIC AND THERAPEUTIC MATERIALS; HUMANS; MUCOSITIS; NAIL DISEASES; NEOPLASMS; NEUTROPHILS; PIGMENTATION DISORDERS; PROTEASOME INHIBITORS; PROTEIN KINASE INHIBITORS; RADIODERMATITIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SKIN NEOPLASMS;

EID: 84906544828     PISSN: 10855629     EISSN: 15580768     Source Type: Journal    
DOI: 10.12788/j.sder.0060     Document Type: Article

References (127)

1. Barasch A, Epstein JB. Management of cancer therapy-induced oral mucositis. Dermatol Ther. 2011;24(4):424-431.
2. Öhrn KE, Wahlin YB, Sjoden PO. Oral status during radiotherapy and chemotherapy: a descriptive study of patients experiences and the occurrence of oral complications. Support Care Cancer. 2001;9:247-257.
3. Peterson DE, Ohrn K, Bowen J, et al. Systematic review of oral cryotherapy for management of oral mucositis caused by cancer therapy. Support Care Cancer. 2013;21(1):327-332.
4. Stiff PJ, Emmanouilides C, Bensinger WI, et al. Palifermin reduces patient-reported mouth and throat soreness and improves patient functioning in the hematopoietic stem-cell transplantation setting. J Clin Oncol. 2006;24(33):5186-5193.
5. Spielberger R, Stiff P, Bensinger W, et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med. 2004: 351: 2590-2598.
6. Silva GB, Mendonça EF, Bariani C, Antunes HS, Silva MA. The prevention of induced oral mucositis with low-level laser therapy in bone marrow transplantation patients: a randomized clinical trial. Photomed Laser Surg. 2011;29(1):27-31.
7. Migliorati C, Hewson I, Lalla RV, et al. Systematic review of laser and other light therapy for the management of oral mucositis in cancer patients. Support Care Cancer. 2013;21(1):333-341.
8. Saunders DP, Epstein JB, Elad S, et al. Systematic review of antimicrobials, mucosal coating agents, anesthetics, and analgesics for the management of oral mucositis in cancer patients. Support Care Cancer. 2013;21(11):3191-3207.
9. Nicolatou-Galitis O, Sarri T, Bowen J, et al. Systematic review of anti-inflammatory agents for the management of oral mucositis in cancer patients. Support Care Cancer. 2013;21(11):3179-3189.
10. Nicolatou-Galitis O, Sarri T, Bowen J, et al. Systematic review of amifostine for the management of oral mucositis in cancer patients. Support Care Cancer. 2013;21(1):357-364.
11. Jensen SB, Jarvis V, Zadik Y, et al. Systematic review of miscellaneous agents for the management of oral mucositis in cancer patients. Support Care Cancer. 2013;21(11):3223-3232.
12. Yeager CE, Olsen EA. Treatment of chemotherapy-induced alopecia. Dermatol Ther. 2011;24(4):432-442.
13. Palamaras I, Misciali C, Vincenzi C, Robles WS, Tosti A. Permanent chemotherapyinduced alopecia: a review. J Am Acad Dermatol. 2011;64(3):604-606.
14. van den Hurk CJ, Peerbooms M, van de Poll-Franse LV, Nortier JW, Coebergh JW, Breed WP. Scalp cooling for hair preservation and associated characteristics in 1411 chemotherapy patients - results of the Dutch Scalp Cooling Registry. Acta Oncol. 2012;51(4):497-504.
15. Lotfi-Jam K, Carey M, Jefford M, Schofield P, Charleson C, Aranda S. Nonpharmacologic strategies for managing common chemotherapy adverse effects: a systematic review. J Clin Oncol. 2008;26(34):5618-5629.
16. Komen MM, Smorenburg CH, van den Hurk CJ, Nortier JW. Factors influencing the effectiveness of scalp cooling in the prevention of chemotherapy-induced alopecia. Oncologist. 2013;18(7):885-891.
17. Rodriguez R, Machiavelli M, Leone B, et al. Minoxidil (Mx) as a prophylaxis of doxorubicin--induced alopecia. Ann Oncol. 1994;5(8):769-770.
18. Granai CO, Frederickson H, Gajewski W, Goodman A, Goldstein A, Baden H. The use of minoxidil to attempt to prevent alopecia during chemotherapy for gyneconlogic malignancies. Eur J Gynaecol Oncol. 1991;12(2):129-132.
19. Duvic M, Lemak NA, Valero V, et al. A randomized trial of minoxidil in chemotherapy-induced alopecia. J Am Acad Dermatol. 1996;35(1):74-78.
20. Vassallo C, Brazzelli V, Ardigò M, Borroni G. The irreplaceable image: Nails changes in onco-hematologic patients. Haematologica. 2001;86(3):334-336.
21. Gilbar P, Hain A, Peereboom VM. Nail toxicity induced by cancer chemotherapy. J Oncol Pharm Pract. 2009;15(3):143-155.
22. Langer SW. Extravasation of chemotherapy. Curr Oncol Rep. 2010;12(4):242-246.
23. Schulmeister L. Extravasation management: clinical update. Semin Oncol Nurs. 2011;27(1):82-90.
24. Mouridsen HT, Langer SW, Buter J, et al. Treatment of anthracycline extravasation with Savene (dexrazoxane): results from two prospective clinical multicentre studies. Ann Oncol. 2007;18(3):546-550.
25. Owen OE, Dellatorre DL, Van Scott EJ, Cohen MR. Accidental intramuscular injection of mechlorethamine. Cancer. 1980;45(8):2225-2226.
26. Bertelli G, Dini D, Forno GB, et al. Hyaluronidase as an antidote to extravasation of Vinca alkaloids: clinical results. J Cancer Res Clin Oncol. 1994;120(8):505-506.
27. Huang V, Anadkat M. Dermatologic manifestations of cytotoxic therapy. Dermatol Ther. 2011;24(4):401-410.
28. Rosen AC, Balagula Y, Raisch DW, et al. Life-threatening dermatologic adverse events in oncology. Anticancer Drugs. 2013; Oct 8 [Epub ahead of print].
29. Burris HA 3rd, Hurtig J. Radiation recall with anticancer agents. Oncologist. 2010;15(11):1227-1237.
30. Mizumoto M, Harada H, Asakura H, et al. Frequency and characteristics of docetaxel-induced radiation recall phenomenon. Int J Radiat Oncol Biol Phys. 2006;66(4):1187-1191.
31. Camidge R, Price A. Characterizing the phenomenon of radiation recall dermatitis. Radiother Oncol. 2001;59(3):237-245.
32. Smith KJ, Germain M, Skelton H. Histopathologic features seen with radiation recall or enhancement eruptions. J Cutan Med Surg. 2002;6:535-540.
33. Ee HL, Yosipovitch G. Photo recall phenomenon: an adverse reaction to taxanes. Dermatology. 2003;207:196-198.
34. Bolognia JL, Cooper DL, Glusac EJ. Toxic erythema of chemotherapy: a useful clinical term. J Am Acad Dermatol. 2008;59(3):524-529.
35. Horn TD. Antineoplastic chemotherapy, sweat, and the skin. Arch Dermatol. 1997;133(7):905-906.
36. Degen A, Alter M, Schenck F, et al. The hand-foot-syndrome associated with medical tumor therapy - classification and management. J Dtsch Dermatol Ges. 2010;8(9):652-661.
37. Zimmerman GC, Keeling JH, Lowry M, Medina J, Von Hoff DD, Burris HA. Prevention of docetaxel-induced erythrodysesthesia with local hypothermia. J Natl Cancer Inst. 1994;86(7):557-558.
38. Zhang RX, Wu XJ, Wan DS, et al. Celecoxib can prevent capecitabine-related handfoot syndrome in stage II and III colorectal cancer patients: result of a single-center, prospective randomized phase III trial. Ann Oncol. 2012;23(5):1348-1353.
39. Corrie PG, Bulusu R, Wilson CB, et al. A randomised study evaluating the use of pyridoxine to avoid capecitabine dose modifications. Br J Cancer. 2012;107(4):585-587.
40. Chen M, Zhang L, Wang Q, Shen J. Pyridoxine for prevention of hand-foot syndrome caused by chemotherapy: a systematic review. PLoS One. 2013;8(8):e72245.
41. Teresi ME, Murry DJ, Cornelius AS. Ifosfamide-induced hyperpigmentation. Cancer. 1993;71(9):2873-2875.
42. Chittari K, Tagboto S, Tan BB. Cyclophosphamide-induced nail discoloration and skin hyperpigmentation: a rare presentation. Clin Exp Dermatol. 2009;34(3):405-406.
43. Abess A, Keel DM, Graham BS. Flagellate hyperpigmentation following intralesional bleomycin treatment of verruca plantaris. Arch Dermatol. 2003;139(3):337-339.
44. Vuerstaek JD, Frank J, Poblete-Gutiérrez P. Bleomycin-induced flagellate dermatitis. Int J Dermatol. 2007;46(S3):3-5.
45. Al-Lamki Z, Pearson P, Jaffe N. Localized cisplatin hyperpigmentation induced by pressure. A case report. Cancer. 1996;77(8):1578-1581.
46. Singal R, Tunnessen WW Jr, Wiley JM, Hood AF. Discrete pigmentation after chemotherapy. Pediatr Dermatol. 1991;8(3):231-235.
47. Sánchez Henarejos P, Ros Martínez S, Marín Zafra GR, Alonso Romero JL, Navarrete Montoya A. Intertrigo-like eruption caused by pegylated liposomal doxorubicin (PLD). Clin Transl Oncol. 2009;11(7):486-487.
48. Rosman IS, Lloyd BM, Hayashi RJ, Bayliss SJ. Cutaneous effects of thiotepa in pediatric patients receiving high-dose chemotherapy with autologous stem cell transplantation. J Am Acad Dermatol. 2008;58(4):575-578.
49. Almagro BM, Steyls MC, Navarro NL, et al. Occurrence of subacute cutaneous lupus erythematosus after treatment with systemic fluorouracil. J Clin Oncol. 2011;29(20):e613-615.
50. Fernandes NF, Rosenbach M, Elenitsas R, Kist JM. Subacute cutaneous lupus erythematosus associated with capecitabine monotherapy. Arch Dermatol. 2009;145(3):340-341.
51. Wiznia LE, Subtil A, Choi JN. Subacute cutaneous lupus erythematosus induced by chemotherapy: gemcitabine as a causative agent. JAMA Dermatol. 2013;149(9):1071-1075.
52. Nanney LB, Stoscheck CM, King LE Jr., Underwood RA, Holbrook KA. Immunolocalization of epidermal growth factor receptors in normal developing human skin. J Invest Dermatol. 1990;94:742-748.
53. Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer. 2006;6(10):803-812.
54. Wu PA, Balagula Y, Lacouture ME, Anadkat MJ. Prophylaxis and treatment of dermatologic adverse events from epidermal growth factor receptor inhibitors. Curr Opin Oncol. 2011;23(4):343-351.
55. Lacouture ME, Anadkat MJ, Bensadoun RJ, et al. MASCC Skin Toxicity Study Group. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer. 2011;19(8):1079-1095.
56. Iressa [package insert]. Chesire, UK: AstraZeneca Pharmaceuticals; 2005.
57. Tarceva [package insert]. Melville, NY: OSI Pharmaceuticals; 2010.
58. Erbitux [package insert]. Branchburg, NJ: ImClone LLC; 2010.
59. Vectibix [package insert]. Thousand Oaks, CA: Amgen Inc; 2010.
60. Brodell LA, Hepper D, Lind A, Gru AA, Anadkat MJ. Histopathology of acneiform eruptions in patients treated with epidermal growth factor receptor inhibitors. J Cutan Pathol. 2013; Jul 26 [Epub ahead of print]. doi: 10.1111/cup.12202.
61. Jost M, Kari C, Rodeck U. The EGF receptor - an essential regulator of multiple epidermal functions. Eur J Dermatol. 2000;10(7):505-510.
62. Mascia F, Mariani V, Girolomoni G, Pastore S. Blockade of the EGF receptor induces a deranged chemokine expression in keratinocytes leading to enhanced skin inflammation. Am J Pathol. 2003;163(1):303-312.
63. Liu HB, Wu Y, Lv TF, et al. Skin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: a systematic review and meta-analysis. PLoS One. 2013;8(1):e55128.
64. Stintzing S, Kapaun C, Laubender RP, et al. Prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: results from a randomized trial of the GERMAN AIO CRC Study Group. Int J Cancer. 2013;132(1):236-245.
65. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010;11:21-28.
66. Aranda E, Manzano JL, Rivera F, et al. Phase II open-label study of erlotinib in combination with gemcitabine in unresectable and/or metastatic adenocarcinoma of the pancreas: relationship between skin rash and survival (Pantar study). Ann Oncol. 2012;23(7):1919-1925.
67. Petrelli F, Borgonovo K, Cabiddu M, Lonati V, Barni S. Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: a literature-based meta-analysis of 24 trials. Lung Cancer. 2012;78(1):8-15.
68. Gordon AN, Finkler N, Edwards RP, et al. Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: Results from a phase II multicenter study. Int J Gynecol Cancer. 2005;15:785-792.
69. Rosen AC, Case EC, Dusza SW, et al. Impact of dermatologic adverse events on quality of life in 283 cancer patients: a questionnaire study in a dermatology referral clinic. Am J Clin Dermatol. 2013;14(4):327-333.
70. Chiang HC, Anadkat MJ. Isotretinoin for high-grade or refractory epidermal growth factor receptor inhibitor-related acneiform papulopustular eruptions. J Am Acad Dermatol. 2013;69(4):657-658.
71. Li T, Perez-Soler R. Skin toxicities associated with epidermal growth factor receptor inhibitors. Target Oncol. 2009;4(2):107-119.
72. Jatoi, A. Menadione Topical Lotion in Treating Skin Discomfort and Psychological Distress in Patients With Cancer Receiving Panitumumab, Erlotinib Hydrochloride, or Cetuximab. Identifier: NCT01393821. ClinicalTrials.gov. http://clinicaltrials.gov/ct2/show/NCT01393821?term=NCT01393821.&rank=1 Identifier: NCT01393821. Accessed: January 12, 2014.
73. Jatoi A, Thrower A, Sloan JA, et al. Does sunscreen prevent epidermal growth factor receptor (EGFR) inhibitor-induced rash? Results of a placebo-controlled trial from the North Central Cancer Treatment Group (N05C4). Oncologist. 2010;15(9):1016-1022.
74. Eilers RE Jr, Gandhi M, Patel JD, Mulcahy MF, Agulnik M, Hensing T, Lacouture ME. Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy. J Natl Cancer Inst. 2010;102(1):47-53.
75. Tejwani A, Wu S, Jia Y, Agulnik M, Millender L, Lacouture ME. Increased risk of high-grade dermatologic toxicities with radiation plus epidermal growth factor receptor inhibitor therapy. Cancer. 2009;115(6):1286-1299.
76. Bernier J, Russi EG, Homey B, et al. Management of radiation dermatitis in patients receiving cetuximab and radiotherapy for locally advanced squamous cell carcinoma of the head and neck: proposals for a revised grading system and consensus management guidelines. Ann Oncol. 2011;22(10):2191-2200.
77. Yalçin S, Dizdar O, Yalçin B, Gököz O. Sparing of previously irradiated skin from erlotinib-induced acneiform rash. J Am Acad Dermatol. 2008;58(1):178-179.
78. Osio A, Mateus C, Soria JC, et al. Cutaneous side-effects in patients on longterm treatment with epidermal growth factor receptor inhibitors. Br J Dermatol. 2009;161(3):515-521.
79. Lacouture ME, Lai SE. The PRIDE (Papulopusutles and/or paronychia, Regulatory abnormalities of hair growth, Itching, and Dryness due to Epidermal growth factor receptor inhibitors) syndrome. Br J Dermatol. 2006;155(4):852-854.
80. Yang BH, Bang CY, Byun JW, et al. A case of cicatricial alopecia associated with erlotinib. Ann Dermatol. 2011;23(S3):S350-353.
81. Carser JE, Summers YJ. Trichomegaly of the eyelashes after treatment with erlotinib in non-small cell lung cancer. J Thorac Oncol. 2006;1(9):1040-1041.
82. Murillas R, Larcher F, Conti CJ, Santos M, Ullrich A, Jorcano JL. Expression of a dominant negative mutant of epidermal growth factor receptor in the epidermis of transgenic mice elicits striking alterations in hair follicle development and skin structure. EMBO J. 1995;14(21):5216-5223.
83. Hu JC, Sadeghi P, Pinter-Brown LC, Yashar S, Chiu MW. Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management. J Am Acad Dermatol. 2007;56(2):317-326.
84. Fischer A, Rosen AC, Ensslin CJ, Wu S, Lacouture ME. Pruritus to anticancer agents targeting the EGFR, BRAF, and CTLA-4. Dermatol Ther. 2013;26(2):135-148.
85. Zhang L, Zhou Q, Ma L, Wu Z, Wang Y. Meta-analysis of dermatological toxicities associated with sorafenib. Clin Exp Dermatol. 2011;36(4):344-350.
86. Rosenbaum SE, Wu S, Newman MA, West DP, Kuzel T, Lacouture ME. Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib. Support Care Cancer. 2008;16(6):557-566.
87. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006;368(9544):1329-1338.
88. Robert C, Spatz A, Faivre S et al. Tyrosine kinase inhibition and grey hair. Lancet. 2003;361:1056.
89. Robert C, Faivre S, Raymond E, Armand JP, Escudier B. Subungual splinter hemorrhages: a clinical window to inhibition of vascular endothelial growth factor receptors? Ann Intern Med. 2005;143(4):313-314.
90. Robert C, Mateus C, Spatz A, Wechsler J, Escudier B. Dermatologic symptoms associated with the multikinase inhibitor sorafenib. J Am Acad Dermatol. 2009;60(2):299-395.
91. Fraunfelder FW, Solomon J, Druker BJ, Esmaeli B, Kuyl J. Ocular side-effects associated with imatinib mesylate (Gleevec). J Ocul Pharmacol Ther. 2003;19(4):371-375.
92. Dubauskas Z, Kunishige J, Prieto VG, Jonasch E, Hwu P, Tannir NM. Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib. Clin Genitourin Cancer. 2009;7(1):20-23.
93. Arnault JP, Wechsler J, Escudier B, et al. Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib. J Clin Oncol. 2009;27(23):59-61.
94. Breaker K, Naam M, La Rosa FG, Flaig IP, Flaig TW. Skin cancer associated with the use of sorafenib and sunitinib for renal cell carcinoma. Dermatol Surg. 2013;39(7):981-987. 206
95. Lacouture ME, Reilly LM, Gerami P, Guitart J. Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib. Ann Oncol. 2008;19(11):1955-1961.
96. Azad NS, Aragon-Ching JB, Dahut WL, et al. Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy. Clin Cancer Res. 2009;15(4):1411-1416.
97. Faivre S, Delbaldo C, Vera K, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol. 2006;24(1):25-35.
98. Raanani P, Goldman JM, Ben-Bassat I. Depigmentation in a chronic myeloid leukemia patient treated with STI-571. J Clin Oncol. 2002;20:869-870.
99. Fava P, Stroppiana E, Savoia P, Bernengo MG. Halo nevi related to treatment with imatinib in a dermatofibrosarcoma protuberans patient. J Eur Acad Dermatol Venereol. 2010;24(2):244-245.
100. Campbell T, Felsten L, Moore J. Disappearance of lentigines in a patient receiving imatinib treatment for familial gastrointestinal stromal tumor syndrome. Arch Dermatol. 2009;145(11):1313-1316.
101. Botchkareva NV, Khlgatian M, Longley BJ, Botchkarev VA, Gilchrest BA. SCF/ckit signaling is required for cyclic regeneration of the hair pigmentation unit. FASEB J. 2001;15(3):645-658.
102. McClelland CM, Harocopos GJ, Custer PL. Periorbital edema secondary to imatinib mesylate. Clin Ophthalmol. 2010;4:427-431.
103. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344(14):1031-1037.
104. Rodt SA, Ahlén K, Berg A, Rubin K, Reed RK. A novel physiological function for platelet-derived growth factor-BB in rat dermis. J Physiol. 1996;495(1):193-200.
105. Pietras K, Ostman A, Sjöquist M, et al. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res. 2001;61(7):2929-2934.
106. Liu D, Seiter K, Mathews T, Madahar CJ, Ahmed T. Sweet's syndrome with CML cell infiltration of the skin in a patient with chronic-phase CML while taking imatinib mesylate. Arch Dermatol. 2005;141(3):368-370.
107. Dib EG, Ifthikharuddin JJ, Scott GA, Partilo SR. Neutrophilic eccrine hidradenitis induced by imatinib mesylate (Gleevec) therapy. Leuk Res. 2005;29(2):233-234.
108. Schwarz M, Kreuzer KA, Baskaynak G, Dörken B, le Coutre P. Imatinib-induced acute generalized exanthematous pustulosis (AGEP) in two patients with chronic myeloid leukemia. Eur J Haematol. 2002;69(4):254-256.
109. Pinato DJ, Sharma R. Imatinib induced pyoderma gangrenosum. J Postgrad Med. 2013;59(3):244-245.
110. Ueharaguchi Y, Kabashima K, Sasahashi M, Matsuda A, Matubara K, Matsui M. A case of pyoderma gangrenosum possibly associated with sunitinib treatment. Int J Dermatol. 2013;52(5):634-636.
111. Smith KJ, Haley H, Hamza S, Skelton HG. Eruptive keratoacanthoma-type squamous cell carcinomas in patients taking sorafenib for the treatment of solid tumors. Dermatol Surg. 2009;35(11):1766-1770.
112. Huang V, Hepper D, Anadkat M, Cornelius L. Cutaneous toxic effects associated with vemurafenib and inhibition of the BRAF pathway. Arch Dermatol. 2012;148(5):628-633.
113. Arnault JP, Mateus C, Escudier B, et al. Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1. Clin Cancer Res. 2012;18(1):263-272.
114. Anforth R, Blumetti TC, Clements A, Kefford R, Long GV, Fernandez-Penas P. Systemic retinoids for the chemoprevention of cutaneous squamous cell carcinoma and verrucal keratosis in a cohort of patients on BRAF inhibitors. Br J Dermatol. 2013; Jul 20 [Epub ahead of print]. doi: 10.1111/bjd.12519.
115. Scheinfeld N. Imatinib mesylate and dermatology part 2: a review of the cutaneous side effects of imatinib mesylate. J Drugs Dermatol. 2006;5(3):228-231.
116. Kawakami Y, Nakamura K, Nishibu A, Yanagihori H, Kimura H, Yamamoto T. Regression of cutaneous squamous cell carcinoma in a patient with chronic myeloid leukaemia on imatinib mesylate treatment. Acta Derm Venereol. 2008;88(2):185-186.
117. Mir-Bonafé JM, Cañueto J, Bravo J, de Unamuno P. Improvement of actinic keratosis associated with sunitinib therapy for metastatic renal cell carcinoma. Int J Dermatol. 2013;52(11):1445-1447.
118. Brouard M, Saurat JH. Cutaneous reactions to STI571. N Engl J Med. 2001;345(8):618-619.
119. Gerecitano J, Goy A, Wright J, et al. Drug-induced cutaneous vasculitis in patients with non-Hodgkin lymphoma treated with the novel proteasome inhibitor bortezomib: a possible surrogate marker of response? Br J Haematol. 2006;134(4):391-398.
120. Pour L, Hajek R, Zdenek A, Krejci M, Krivanova A, Vorlicek J. Skin lesions induced by bortezomib. Haematologica. 2005;90(12):44.
121. Garcia-Navarro X, Puig L, Fernández-Figueras MT, Dalmau J, Roe E, Alomar A. Bortezomib-associated cutaneous vasculitis. Br J Dermatol. 2007;157(4):799-801.
122. Villarrubia B, Betlloch I, Mataix J, Lucas A, Botella C. Bortezomib-associated rash: a new recognizable and avoidable side-effect. Br J Dermatol. 2007;156(4):784-785.
123. Van Regenmortel N, Van de Voorde K, De Raeve H, et al. Bortezomib-induced Sweet's syndrome. Haematologica. 2005;90(12):43.
124. Lawrence T, Gilroy DW, Colville-Nash PR, Willoughby DA. Possible new role for NF-kappaB in the resolution of inflammation. Nat Med. 2001;7(12):1291-1297.
125. Mangiacavalli S, Zappasodi P, Castagnola C, et al. Severe intestinal vasculitis in a patient under treatment with bortezomib. Ann Hematol. 2007;86(12):923-924.
126. Pitini V, Arrigo C, Altavilla G, Naro C. Severe pulmonary complications after bortezomib treatment for multiple myeloma: an unrecognized pulmonary vasculitis? Leuk Res. 2007;31(7):1027-1028.
127. Fang B, Song Y, Ma J, Zhao RC. Severe epidermal necrolysis after bortezomib treatment for multiple myeloma. Acta Haematol. 2007;118(2):65-67.